Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARGE: Ribociclib and Belinostat in Metastatic TNBC and Recurrent Ovarian Cancer
NCT04315233Phase 1Terminated
- Sponsor
- University of Utah
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribociclib and belinostat in triple negative breast cancer (TNBC) and ovarian cancer (2 cohorts), sponsored by University of Utah. Primary endpoint: Dose Limiting Toxicity at 28 days. Started May 2021; status: terminated.
02
Drugs
ribociclibbelinostat
03
Conditions
triple negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NCT04315233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315233.